The MiCardia Corporation of Irvine, California has announced the completion of the first U.S. implant of its Dynaplasty mitral valve repair technology.

MiCardia is developing Dynaplasty® technology for the treatment of structural heart disease, focusing initially on mitral and tricuspid valve disorders and as a method of interrupting a major element in the onset and progression of Heart Failure.

The full new item can be found here.